|
Clinical characteristics
|
|
Age (y)
|
54 (47–63)
|
55 (48–63)
|
53 (46–63)
|
0.38
|
56 (48–67)
|
52 (46–63)
|
0.22
|
|
Male, n (%)
|
191 (88)
|
99 (90.8)
|
92 (85.2)
|
0.20
|
93 (85.3)
|
98 (90.7)
|
0.21
|
|
Body mass index, kg/m2
|
24.2 (22.2–26.9)
|
23.8 (21.5–26.8)
|
24.8 (22.5–27.1)
|
0.33
|
24.2(21.4–27.1)
|
23.8 (22.4–26.6)
|
0.62
|
|
CAD risk factors, n (%)
|
|
Hypertension
|
129 (59.4)
|
68 (62.4)
|
61 (56.5)
|
0.37
|
66 (60.6)
|
63 (58.3)
|
0.73
|
|
Diabetes mellitus
|
65 (30)
|
31 (28.4)
|
34 (31.5)
|
0.62
|
30 (27.5)
|
35 (32.4)
|
0.43
|
|
Dyslipidemia
|
53 (24.4)
|
29 (26.6)
|
24 (22.2)
|
0.45
|
28 (25.7)
|
25 (23.1)
|
0.66
|
|
Smoking
|
168 (77.4)
|
86 (78.9)
|
82 (75.9)
|
0.60
|
81 (74.3)
|
87 (80.6)
|
0.27
|
|
Family History
|
34 (15.7)
|
14 (12.8)
|
20 (18.5)
|
0.25
|
19 (17.6)
|
15 (13.8)
|
0.43
|
|
Symptom onset > 6 h, n (%)
|
105 (48.4)
|
48 (44.0)
|
57 (52.8)
|
0.19
|
48 (44.0)
|
57 (52.8)
|
0.19
|
|
Anterior MI, n (%)
|
112 (51.6)
|
56 (51.4)
|
56 (51.9)
|
0.94
|
58 (53.2)
|
54 (50.0)
|
0.63
|
|
TIMI risk score > 4, n (%)
|
61 (28.1)
|
31 (28.4)
|
30 (27.8)
|
0.91
|
33 (30.3)
|
28 (25.9)
|
0.47
|
|
Killip class II–IV, n (%)
|
41 (18.9)
|
17 (15.6)
|
24 (22.2)
|
0.21
|
17 (15.6)
|
24 (22.2)
|
0.21
|
|
Medication at 24 h, n (%)
|
|
Salicylic acid
|
217 (100)
|
109 (100)
|
108 (100)
|
NA
|
109 (100)
|
108 (100)
|
NA
|
|
Clopidogrel
|
164 (75.6)
|
83 (76.1)
|
81 (75.0)
|
0.84
|
81 (74.3)
|
83 (76.9)
|
0.66
|
|
Ticagrelor
|
53 (24.4)
|
26 (23.9)
|
27 (25)
|
0.84
|
28 (25.7)
|
25 (23.1)
|
0.66
|
|
ACE-inhibitor
|
60 (27.6)
|
24 (22.0)
|
36 (33.3)
|
0.06
|
28 (25.7)
|
32 (29.6)
|
0.51
|
|
Beta-blocker
|
4 (1.8)
|
2 (1.8)
|
1 (1.9)
|
1.00
|
1 (0.9)
|
3 (2.8)
|
0.30
|
|
Statin
|
212 (97.7)
|
106 (97.2)
|
106 (98.1)
|
1.00
|
107 (98.2)
|
105 (97.2)
|
0.68
|
|
Anticoagulation, n (%)
|
66 (30.4)
|
35 (32.1)
|
31 (28.7)
|
0.58
|
33 (30.2)
|
33 (30.5)
|
0.96
|
|
Medications at discharged, n (%)
|
|
Salicylic acid
|
214 (28.6)
|
108 (99.1)
|
106 (98.1)
|
0.62
|
108 (99.1)
|
106 (98.1)
|
0.62
|
|
Clopidogrel
|
164 (75.6)
|
86 (78.9)
|
78 (72.2)
|
0.25
|
82 (75.9)
|
82 (75.9)
|
0.90
|
|
Ticagrelor
|
52 (24.1)
|
23 (21.6)
|
29 (26.9)
|
0.34
|
27 (24.8)
|
25 (23.4)
|
0.80
|
|
ACE-inhibitor
|
189 (87.1)
|
95 (87.2)
|
94 (87.0)
|
0.97
|
95 (87.2)
|
94 (87.0)
|
0.97
|
|
Beta-blocker
|
188 (86.2)
|
95 (87.2)
|
93 (86.1)
|
0.81
|
96 (88.1)
|
92 (85.2)
|
0.53
|
|
Statin
|
217 (100)
|
109 (100)
|
108 (100)
|
NA
|
109 (100)
|
108 (100)
|
NA
|
|
Echocardiography data
|
|
LVEF, (%)
|
48 (40–56)
|
48 (41–56)
|
48 (40–56)
|
0.36
|
50 (41–57.7)
|
46 (39–55)
|
0.02
|
|
Laboratory characteristics
|
|
Hemoglobin, g/dl
|
14.4 (13–15.4)
|
14.6 (13.3–15.5)
|
13.9 (12.8–15.2)
|
0.48
|
14.3 (13.1–15.4)
|
14.6 (13–15.3)
|
0.30
|
|
Leukocyte count, /ul
|
13,230 (11,050–16,130)
|
14,090 (11,140–15,990)
|
12,905 (10,962.5–16,265)
|
0.68
|
13,570 (10,992.5–16,255)
|
13,230 (11,250–16,130)
|
0.64
|
|
Baseline creatinine > 1.3 mg/dl, n (%)
|
38 (16.6)
|
13 (11.9)
|
23 (21.3)
|
0.06
|
18 (16.5)
|
18 (16.7)
|
0.97
|
|
Admission blood glucose level, mg/dl
|
141 (117–201)
|
138 (115–195)
|
144.5 (118.2–207.2)
|
0.44
|
135 (115–199.7)
|
144 (119–202)
|
0.11
|
|
Initial Troponin T, ng/L
|
398 (155–1021)
|
418 (168–1714)
|
389 (139.2–691)
|
0.16
|
319 (152.2–1256)
|
417 (155–962)
|
0.79
|
|
Primary PCI characteristics
|
|
Baseline TIMI flow, n (%)
|
|
0
|
160 (73.7)
|
77 (70.6)
|
83 (76.9)
|
0.29
|
77 (70.6)
|
83 (76.9)
|
0.29
|
|
1
|
11 (5.1)
|
5 (4.6)
|
6 (5.6)
|
0.74
|
6 (5.5)
|
5 (4.6)
|
0.76
|
|
2
|
30 (13.8)
|
19 (17.4)
|
11 (10.2)
|
0.12
|
17 (15.6)
|
13 (12.0)
|
0.44
|
|
3
|
16 (7.4)
|
8 (7.3)
|
8 (7.4)
|
0.98
|
9 (8.3)
|
7 (6.5)
|
0.61
|
|
Final TIMI flow, n (%)
|
|
0
|
2 (0.9)
|
0
|
2 (1.9)
|
0.34
|
1 (0.9)
|
1 (0.9)
|
1.00
|
|
1
|
16 (7.4)
|
8 (7.3)
|
8 (7.4)
|
0.98
|
10 (9.2)
|
6 (5.6)
|
0.30
|
|
2
|
98 (45.2)
|
57 (52.3)
|
41 (38.0)
|
0.03
|
48 (44.0)
|
50 (46.3)
|
0.73
|
|
3
|
101 (46.5)
|
44 (40.4)
|
57 (52.8)
|
0.06
|
50 (45.9)
|
51 (47.2)
|
0.82
|
|
Thrombus grade 4&5, n (%)
|
169 (77.9)
|
83 (76.1)
|
86 (79.6)
|
0.53
|
84 (77.1)
|
85 (78.7)
|
0.77
|
|
Door-to-device time, min
|
64 (54–79)
|
67 (56–80)
|
63 (53–73
|
0.07
|
68 (56.5–83.7)
|
62 (52–73)
|
0.01
|
|
Procedural time, min
|
40 (31–55)
|
40 (31–57)
|
40 (30–52)
|
0.39
|
40 (31.2- 56.5)
|
41 (29–52)
|
0.59
|
|
Radial access, n (%)
|
184 (84.8)
|
90 (82.6)
|
94 (87.0)
|
0.35
|
89 (81.7)
|
95 (88)
|
0.19
|
|
Balloon predilation, n (%)
|
208 (95.9)
|
105(96.3)
|
103 (95.4)
|
0.74
|
103 (94.5)
|
105 (97.2)
|
0.49
|
|
Manual thrombectomy, n (%)
|
3 (2.8)
|
3 (2.8)
|
0
|
0.24
|
2 (1.8)
|
1 (0.9)
|
1.00
|
|
Intracoronary eptifibatide, n (%)
|
10 (4.6)
|
5 (4.6)
|
5 (4.6)
|
1.00
|
4 (3.7)
|
6 (5.6)
|
0.53
|
|
Infarct related artery, n (%)
|
|
Left main
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
LAD
|
113 (52.1)
|
56 (51.4)
|
57 (52.8)
|
0.83
|
57 (52.3)
|
56 (51.9)
|
0.94
|
|
LCX
|
7 (3.2)
|
7 (6.4)
|
0 (0)
|
0.01
|
1 (0.9)
|
6 (5.5)
|
0.05
|
|
RCA
|
97 (44.7)
|
46 (42.2)
|
51 (47.2)
|
0.45
|
46 (42.2)
|
51 (47.2)
|
0.45
|
|
Coronary involvement, n (%)
|
|
1-Vessel disease
|
68 (31.1)
|
32 (29.4)
|
36 (33.3)
|
0.52
|
35 (32.1)
|
33 (30.6)
|
0.80
|
|
2-Vessel disease
|
66 (30.4)
|
35 (32.1)
|
31 (28.7)
|
0.58
|
33 (30.6)
|
33 (30.3)
|
0.96
|
|
3-Vessel disease
|
73 (33.6)
|
40 (36.7)
|
33 (30.6)
|
0.33
|
38 (34.9)
|
35 (32.4)
|
0.70
|
|
Left Main disease
|
10 (4.6)
|
2 (1.8)
|
8 (7.4)
|
0.05
|
3 (2.8)
|
7 (6.5)
|
0.74
|
|
Use of mechanical ventilation, n (%)
|
9 (4.1)
|
4 (3.7)
|
5 (4.6)
|
0.74
|
4 (3.7)
|
5 (4.6)
|
0.74
|
|
Use of DES, n (%)
|
213 (98.2)
|
107 (98.2)
|
106 (98.1)
|
1.00
|
107 (98.2)
|
106 (9.1)
|
1.00
|
